- Home
- DHIL vs DMAC Comparison
DHIL vs DMAC Comparison
Compare DHIL & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHIL
- DMAC
- Stock Information
- Founded
- DHIL 1990
- DMAC 2000
- Country
- DHIL United States
- DMAC United States
- Employees
- DHIL N/A
- DMAC N/A
- Industry
- DHIL Investment Managers
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- DHIL Finance
- DMAC Health Care
- Exchange
- DHIL Nasdaq
- DMAC Nasdaq
- Market Cap
- DHIL 384.0M
- DMAC 321.5M
- IPO Year
- DHIL 1995
- DMAC N/A
- Fundamental
- Price
- DHIL $131.68
- DMAC $5.95
- Analyst Decision
- DHIL
- DMAC Strong Buy
- Analyst Count
- DHIL 0
- DMAC 4
- Target Price
- DHIL N/A
- DMAC $15.50
- AVG Volume (30 Days)
- DHIL 26.5K
- DMAC 303.1K
- Earning Date
- DHIL 10-30-2025
- DMAC 11-12-2025
- Dividend Yield
- DHIL 4.61%
- DMAC N/A
- EPS Growth
- DHIL N/A
- DMAC N/A
- EPS
- DHIL 17.21
- DMAC N/A
- Revenue
- DHIL $149,665,296.00
- DMAC N/A
- Revenue This Year
- DHIL N/A
- DMAC N/A
- Revenue Next Year
- DHIL N/A
- DMAC N/A
- P/E Ratio
- DHIL $7.66
- DMAC N/A
- Revenue Growth
- DHIL 2.65
- DMAC N/A
- 52 Week Low
- DHIL $122.32
- DMAC $3.19
- 52 Week High
- DHIL $172.84
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- DHIL 40.07
- DMAC 42.03
- Support Level
- DHIL $130.11
- DMAC $5.26
- Resistance Level
- DHIL $133.58
- DMAC $6.47
- Average True Range (ATR)
- DHIL 2.58
- DMAC 0.41
- MACD
- DHIL 0.34
- DMAC -0.10
- Stochastic Oscillator
- DHIL 49.64
- DMAC 36.50
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.